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ABSTRACT 
Introduction: Nanotechnology has provided new tools for addressing unmet clinical 
situations, especially in the oncology field. The development of smart nanocarriers able 
to deliver chemotherapeutic agents specifically to the diseased cells and to release them 
in a controlled way has offered a paramount advantage over conventional therapy.  
Areas covered: Among the different types of nanoparticle that can be employed for this 
purpose, inorganic porous materials have received significant attention in the last 
decade due to their unique properties such as high loading capacity, chemical and 
physical robustness, low toxicity and easy and cheap production in the laboratory. This 
review discuss the recent advances performed in the application of porous inorganic and 
metal-organic materials for antitumoral therapy, paying special attention to the 
application of mesoporous silica, porous silicon and metal-organic nanoparticles. 
Expert opinion: The use of porous inorganic nanoparticles as drug carriers for cancer 
therapy has the potential to improve the life expectancy of the patients affected by this 
disease. However, much work is needed to overcome their drawbacks, which are 
aggravated by their hard nature, exploiting the advantages offered by highly the ordered 
pore network of these materials.  
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Article highlights box 
● Porous inorganic nanocarriers present unique characteristics as consequence of their 
ordered pore network such as high loading capacity, ease and cheap synthesis, tunable 
morphology and controlled and sustained drug release profile, among others. 
 
● Pore diameter in these materials can be adjusted within a broad range from 2 nm, 
suitable for small drugs to a few tens of nanometers, useful for the transportation of 
therapeutic macromolecules.  
 
● The external surface of these carriers can be decorated with different (bio)-moieties in 
order to provide targeting abilities against tumoral cells and/or stimuli-responsive 
behavior in the cargo release process. 
 
● These materials present some liabilities in comparison with their organic counterparts 
such as a limited penetration in living tissues as a consequence of their rigid nature. 
Thus, the development of novel strategies which improve their penetration capacity is a 
critical point of their antitumoral efficacy. 
  
1. INTRODUCTION 
In the recent years the scientific community has devoted huge efforts in the search of 
novel treatments against unmet clinical situations such as inoperable cancers, 
degenerative pathologies or resistant infections, among others. The application of 
nanotechnology to medicine, the so called nanomedicine, has become a key discipline 
for the discovery of novel therapies against these terrible diseases. This discipline 
comprises the use of nanometric systems as drug delivery carriers, medical imaging or 
sensors for clinical diagnostics, [1] being the first application the most studied with 
around 76% of the research papers in nanotechnology published in 2014. The utilization 
of nanoparticles as drug carriers provides several advantages such as improved 
pharmacokinetic profile, possibility to employ lipophilic drugs, higher circulation time 
in comparison with the administration of the free drugs and lower toxicity as a 
consequence of the lower dosages employed in the nanovehicles.[2] In 1986, the 
Japanese researchers Maeda and Matsumura reported that macromolecules bigger than 
40 KDa injected in the blood stream tended to accumulate preferably within tumoral 
tissues. They termed this phenomenon as enhanced permeation and retention (EPR 
effect).[3] This preliminary finding paved the way to the use of nanoparticles as drug 
delivery systems for antitumoral applications.[4] The reason for the accumulation of 
nanoparticles and big macromolecules into tumoral areas lies on the characteristic blood 
vessel architecture of tumoral tissues. Tumoral cells show a fast growing rate which 
requires high amounts of nutrients and oxygen. When the size of a tumoral mass 
exceeds 1 mm3 the diffusion of the nutrients is not enough to support the accelerated 
metabolism of the tumoral cells and they begin to suffer starvation. Thus, they force the 
surrounding healthy cells to produce proangiogenic factors which induce the creation of 
novel blood vessels. However, these novel vessels are not properly built, but they 
present pores and fenestrations with diameters up to a few hundreds of nanometers.[5] 
When the nanocarriers reach the tumoral tissue, they are able to pass through these 
fenestrations whereas they cannot pass through blood vessel epithelium present in 
healthy tissues. Additionally, the rapid growing rate of the tumoral cells usually 
compresses the lymphatic vessels compromising their normal function, which causes an 
inefficient drainage in the zone. The lack of a drainage system induces a higher 
retention of the nanoparticles extravasated in the tumoral mass. These two 
characteristics, higher permeability of the tumoral blood vessels (enhanced permeation) 
and lack of efficient lymphatic systems (enhanced retention) explain the preferential 
accumulation of the nanocarriers within the tumoral lesion. Almost 30 years later, a 
countless number of drug delivery nanosystems have been reported for oncological 
applications and even some of them have reached the market.[6] These nanocarriers can 
be formed by organic materials resulting in soft systems such as liposomes, 
polymersomes and micelles, among others, or can exhibit an inorganic nature 
originating tougher systems such as metallic or ceramic nanoparticles.[7]  However, the 
use of pure inorganic materials in nanomedicine is strongly limited and it usually 
requires the creation of hybrid materials which conjugate the advantages of both type of 
systems.[8] Among the different materials that have been employed to build these 
hybrid nanocarriers, those systems which present ordered porosity constitute excellent 
materials for drug delivery applications due to their unique characteristics such as high 
loading capacity, chemical and physical robustness, low toxicity and easy and cheap 
production in the laboratory. The presence of the pore network increases considerably 
the available surface in comparison with solid counterparts. These pores can be 
engineered with a broad range of diameters, from 2 to a few tens of nanometers 
allowing the transportation of therapeutic agents with very different nature, such as 
small drugs, proteins, DNA or RNA strands and even other nanoparticles.  Moreover, 
the ordered porosity of these materials allows more precise control over the drug 
cargo/departure process and also in the own material biodegradation.  In this review, the 
recent advances carried out in the application of porous inorganic and metal-organic 
materials in drug delivery will be presented paying special attention to the application of 
mesoporous silica, porous silicon and metal-organic nanoparticles in antitumoral 
applications. For the synthesis of these materials, the reader could be referred to some 
excellent reviews.[9,10] Additionally, detailed descriptions of the different 
functionalization strategies for the decoration of nanomaterials with different 
(bio)moieties can be found elsewhere.[11]  
2. MESOPOROUS SILICA NANOPARTICLES 
Mesoporous silica nanoparticles (MSNs), specially presenting the MCM-41 structure, is 
a very promising material for drug delivery applications thanks to their specific 
properties. These nanoparticles can be easily obtained in the laboratory showing a wide 
range of morphologies, particle size and pore diameters.[12] MSNs presents high 
loading capacity (600-1000 m2·g-1), high pore volume (0.6-1 mL·g-1) and pore size 
between 2-5 nm. This last property allows the loading of species with very different 
nature, from small molecules to macromolecules such as proteins or DNA which can 
reach sizes of around a few dozens of nanometers. Additionally, the external and/or 
internal surface of these particles can be decorated with different functional groups such 
as amino, thiol or carboxylic groups, among others, using the correspondently 
functionalized alcoxysilanes through direct addition in one pot (co-condensation) or 
after the particle formation (post-synthesis). When a nanocarrier is employed for 
oncological applications, it is particularly important to avoid the premature release of 
the housed drugs due to the highly toxic nature which usually present these therapeutic 
agents. In the case of MSNs, it is possible to avoid the unwanted drug departure 
employing two different strategies. The first one consists in the attachment of different 
moieties (gatekeepers) on the pore outlets through covalent bonds which can be broken 
by an externally applied stimulus (light, magnetic fields, ultrasounds or temperature) or 
by an internal stimulus inherent to the treated pathology (acid or basic environments, 
change in redox conditions, presence of enzymes, etc.)[13] The second strategy for 
controlling the drug release consists in the coating of MSN surface with polymeric or 
lipidic shells which hampers the diffusion of the drugs trapped within the silica 
network.[14] These polymeric or lipid coatings are engineered to allow the drug release 
due to conformational changes in the polymeric layer once exposed to certain stimuli 
(Figure 1). In this section, the recent advances in the development of these stimuli-
responsive materials carried out in the latest years will be briefly described. Due to the 
huge number of stimuli-responsive MSNs which have been reported, these devices will 
be separately described according to the stimulus employed for triggering the release. A 
more exhaustive description of this field has been reviewed elsewhere.[15] 
2.1. Light 
Light irradiation as triggering stimulus provides a precise control of the drug release 
location, being possible to apply the light beam in sub-millimetric regions. 
Contrariwise, its main liability is poor penetration in living tissues. Only light with 
wavelength located in the near infrared (NIR) window (650-1350 nm) is able to 
penetrate a few dozens of millimeters into a tissue. UV and, to a lesser extent, visible 
light, are strongly absorbed by living tissues and their use is limited to exposed or 
transparent regions. After the pioneering work of Fujiwara et al. who described the 
attachment of coumarin molecules on the pore entrances as UV-cleavable 
gatekeepers,[16] many different responsive MSNs which are triggered by UV light have 
been described.[17] Despite the poor penetration of UV light, the application of these 
devices could be possible for the treatment of exposed lesions such as skin, esophagus 
or colon tumors, or the light can be delivered to the target zone using a optic fiber. Lu et 
al. have reported the use of polymeric coatings on the surface of hollow MSN which 
can be degraded by the irradiation with green light (540 nm).[18] Additionally, folic 
acid was conjugated to the polymer branches in order to provide selectivity against 
tumoral cells which overexpress folate receptors showing excellent antitumoral 
response only under light irradiation. A modified azobenzene molecule able to suffer 
photoisomerization with red light (625 nm), which is more penetrating in living tissues, 
has been recently reported as light-sensitive gatekeeper.[19] The group of Thomas Bein 
has widely studied the attachment of photosensitizers (as protoporphyrin IX) on MSN 
surface in order to induce endosomal escape of these carriers when exposed to radiation 
at 405 nm.[20] Nearly all the nanocarriers that are internalized by mammalian cells are 
uptaken via endocytosis. Therefore, to achieve rapid escape from the endosomes is of 
paramount importance for intracellular drug delivery in order to avoid the degradation 
of the transported molecules within late endosomes or lysosomes. Gold nanorods have 
been encapsulated within MSNs for inducing temperature increases in the surroundings 
after NIR exposition due to plasmonic photothermal conversion. Thus, Yang et al. 
employed calix[4]arenes which binds by supramolecular interactions quaternary 
ammonia groups placed on MSN that contains gold nanorods.[21] NIR irradiation 
produces hyperthermia in the region which reduces the binding affinity of the 
calix[4]arenes by the ammonia stalks causing the dissociation of these gatekeepers and 
the subsequent drug departure. Drug-loaded MSNs have been anchored on the surface 
of single-walled carbon nanotubes (SWNT) in order to combine the high loading 
capacity of MSN with the ability to transform NIR into thermal energy of SWNT.[22] 
This hybrid device is able to accumulate into tumoral lesions in a mice model and once 
there, to release its payload under NIR exposition acting simultaneously as contrast 
agent for photoacoustic imaging. Other approaches which exploit NIR-to-visible 
upconversion phenomena[23] and even X-rays[24] have been recently reported 
providing more strategies to the use of light as triggering stimulus. 
2.2. Temperature, magnetic field and ultrasounds 
There are different pathological conditions which are associated with a temperature 
increase. A general approach to achieve temperature-responsive behavior consists in 
coating the external surface of MSN with thermosensitive polymers, mainly based in 
poly(N-isopropylacrylamide) (PNIPAM). This polymer suffers a conformational change 
from linear to globular state when the temperature exceeds 32 oC. A polymeric shell 
placed on the external surface of MSNs act as a diffusion barrier which avoids 
premature release of the housed drugs when the temperature is kept below this value. 
However, if the temperature is higher, the polymer shell collapses and the retained 
drugs are able to escape from the silica matrix. This transition temperature is not useful 
for in vivo applications but it can be tuned to higher values between 40-45 oC adding 
hydrophilic monomers such as acrylamide, acrylic acid or N-hydroxymethylacrylamide 
to the polymer composition. Significant temperature increases can be achieved under 
alternative magnetic fields exposition of MSNs containing superparamagnetic iron 
oxide nanoparticles (SPIONs) trapped inside. Zink et al. have reported that the 
temperature of the particle surroundings can be increased almost 20 ºC after a short time 
magnetic field exposition, depending on the size of the SPIONs trapped within the silica 
matrix.[25] Thus, different engineered polymer coatings have been employed in 
combination with magnetic MSNs in order to control the release of both drugs trapped 
inside the pore network[26] and also higher macromolecules trapped within the polymer 
branches.[27] Moreover, magnetic MSN have been coated with lipid bilayers which are 
spontaneously disrupted at high temperatures.[28] Finally, DNA or peptide motifs have 
also been used as temperature responsive gatekeepers. [29] 
Recently, Paris et al. have described the use of ultrasounds as triggering stimulus for 
drug release.[30] In this case, MSN surface was coated with a thermosensitive polymer 
which contains 2-tetrahydropyranyl methacrylate (THPMA) as monomer sensitive to 
ultrasounds. This polymer collapses at physiological temperature (37 ºC) sealing the 
pore entrances, thus avoiding drug leakage. Under ultrasound irradiation, the acetal 
group of THPMA is broken enhancing the hydrophillicity of the polymer shell which 
places the transition temperature above this temperature and therefore, produces the 
pore opening. 
2.3. pH 
A nanoparticle which is travelling through the body will experience significant pH 
variations, from neutral pH in the blood stream to mild acidic conditions (pH 5.5-6) in 
tumoral, inflamed and infected tissues. Additionally, the pH inside the cells is generally 
more acidic than the pH present in the intracellular media, especially in endosomes and 
lysosomes. Therefore, it is possible to exploit this fact in order to design nanocarriers 
able to release their payloads when they reach these intracellular organelles. One well 
established strategy to synthesize pH-sensitive MSN is to coat the MSN external surface 
with polymers which present neutral charge at physiological pH, whereas they become 
positively charged under mild-acidic conditions.[31] The dense polymer layer hampers 
the drug release at neutral pH but if pH drops to certain values, the repulsion forces 
exerted between charged chains distort the polymer layer allowing the drug departure. 
Another approach is the use of pore blockers which are attached on the pore outlets 
through sensitive bonds which are broken at mild-acidic conditions. Cai et al. have 
recently reported the development of hollow MSNs which exhibit a cascade process 
triggered by pH.[32] The particle surface is functionalized with beta-cyclodextrins (β-
CDs) through boronate bonds. β-CDs bind to adamantane groups attached to PEG 
chains through imine bonds producing the pore closure. When the particle reaches the 
tumoral area (pH = 6.8), the imine bonds are broken causing the PEG detachment which 
enhance the particle internalization by the tumoral cells. Then, as a consequence of the 
more acidic environment within endosomes (pH = 4.5-6.5) boronate bonds suffer 
cleavage triggering the drug release. β-CDs bound to MSN surface by boronate bonds 
have been employed for the fabrication of  MSNs responsive not only to pH variations 
but also to the presence of fructose exploiting the affinity of  vincinal diols present in 
sugar moieties with the boronate group.[33] Lu et al. have described the use of small 
lanthanide nanoparticles as pore blockers which are bound to the pore outlets through 
acid-sensitive acetal bonds.[34] This device is able to release cytotoxic compounds 
loaded inside the pore network, acting at the same time as magnetic resonance imaging 
(MRI) contrast agent thanks to the presence of the rare-earth oxides. Zink et al. have 
recently described a MSN device able to release antibiotics in a pH-triggered manner in 
order to destroy bacteria (F. tularensis) infecting human cells.[35] The pore 
closure/opening mechanism is based on supramolecular interactions between 
anilinoalkane attached on MSN surface and different cyclodextrins. Villegas et al. have 
recently published the decoration of the external surface of MSN with pH sensitive 
polymeric nanocapsules which contain collagenase trapped within their structure.[36] 
Thus, when the nanocarrier reaches the tumoral area, the acidic environment present in 
the tissue causes the disintegration of the polymeric capsule releasing collagenase which 
starts the degradation of the tumoral extracellular matrix. Therefore, an enhanced 
penetration of the nanocarrier is achieved which is of paramount importance in order to 
accomplish a homogeneous distribution of the nanomedicine along the diseased tissue 
(Figure 2). 
2.4. Redox 
 The intracellular media is enriched in reductive species such as glutathione (GSH) in 
comparison with the extracellular environment. One approach to exploit this imbalance 
for triggering drug release is to attach polymers or pore blockers on the particle surface 
using dithiol bonds (S-S) which are broken by the presence of GSH.[37] Additionally, 
the polymer itself can be formed using redox-sensitive monomers or crosslinkers.[38] 
Shi et al. have synthesized hollow MSNs with large pores (24 nm of diameter, average) 
decorated with poly (β-amino esters) through dithiol bonds in order to deliver, in a 
redox responsive manner, siRNA and doxorubicin, simultaneously.[39] Kim et al. have 
described the use of specific Fmoc-functionalized peptide chains which contain a S-S 
bond as redox-sensitive pore blocker.[40] These peptides adopt a specific turn-like 
conformation when attached on the pore entrance, avoiding the drug release. The 
addition of GSH produces a conformational change to a random structure allowing the 
retained drug to leak out from the particle. Finally, in a very recent work, De Cola et al. 
have reported a very interesting approach which consists in the preparation of MSNs 
containing breakable S-S- bonds within the silica framework in such a way that they are 
able to undergo accelerated degradation when exposed to the reductive intracellular 
media.[41] 
2.5. Macro- and small-molecules 
There are different pathologies in which certain enzymes or molecules are produced 
more abundantly than in the healthy state. In the case of oncology, tumoral cells of solid 
tumors usually overexpress proteolytic enzymes as metalloproteinases (MMP) or 
cathepsins in order to degrade the extracellular matrix and colonize other tissues. Avidin 
has been anchored on MSN surface by a biotynilated peptide chain which contains a 
sequence sensitive to MMP-9.[42] This device has been able to deliver two therapeutic 
agents (cisplatin and proteasome inhibitor bortezomib) specifically to tumoral cells in ex 
vivo 3D lung tissue cultures without affecting the healthy cells also present in the 
tumoral mass.  Zhu et al. have recently described a very interesting MSN device able to 
release its payload in the presence of micro-RNA (miR-21) which is overexpressed by 
several tumoral cells.[43] This system is composed by MSN which contains quantum 
dots housed within the silica matrix in order to allow its traceability by fluorescence 
microscopy. The external surface is decorated with specific DNA strands which bind, 
by complementarity, hybrid DNA strands which contain the anti-miR-21 sequence and 
the AS1411 aptamer, this last in charge of the recognition of the tumoral cells. This 
hybrid structure acts as reversible pore blocker and targeting agent at the same time and 
it can be uncapped by the exposition to miR-21. Additionally, the presence or the higher 
concentration of small molecules or ions in pathological tissues can be exploited for 
triggering drug release. Au nanoparticles, as removable caps, have been anchored to the 
pore outlets using Cu2+ complexes as binding ion.[44] These copper complexes are 
broken at low pH values (< 5) and also in the presence of higher concentration of ATP 
(> 4mM).  
3. POROUS SILICON NANOPARTICLES 
Porous silicon nanoparticles (PSiNP) are composed by crystalline silicon crossed by 
multitude of pores with diameters comprised between 5-20 nm. Similarly to MSNs 
mentioned in the previous section, PSiNP present interesting properties for drug 
delivery applications such as high loading capacity (external surface of 200-500 m2·g-1 
and pore volume of 0.5-2 cm3·g-1) excellent biocompatibility, biodegradability and non-
immunogenic nature. Additionally, there are wide number of strategies for surface 
functionalization with different (bio)-moieties which provide targeting or stealth 
capacities in living hosts. Unlike MSNs which are synthesized using bottom-up 
approaches, PSiNP are generally produced by top-bottom strategies such as etching 
(chemical, laser-induced, metal-assisted, chemical vapor, etc.) and milling.[45] The 
PSiNP surface can be chemically modified previous or after the nanoparticle formation 
by different techniques as oxidation, carbonization and hydrosilylation. PSiNP are 
generally loaded by capillarity once the particles are immersed into a concentrated 
solution of the compound to be trapped. Positively charged molecules are more retained 
in this material than neutral or negative molecules due to the intrinsic negative charge of 
PSiNP. Additionally, the drugs or cargo molecules can be covalently attached in the 
pore walls. The attached drugs are released to the surrounding media once the material 
is degraded, or due to the rupture of the covalent bonds which bind the drug on the pore 
walls. Other option to retain molecules within the pore network consists in the oxidation 
of PSiNP after the loading procedure. Thus, the pore openings are closed which retain 
the drugs trapped as a consequence of the volume expansion caused by the oxygen 
incorporation.[46] Finally, when PSiNP are administered into a living organism is 
degraded to silicic acid, which is a harmless compound. PSiNP which contains large 
pores are rapidly degraded (8 hours) in PBS at pH = 7.2. However, this time is higher in 
the case of PSiNP with small pores (<10 nm) or it can be extended by external 
functionalization with different groups or polymers as PEG. In this section, some 
representative advances carried out with PSiNP will be briefly described in order to 
provide a panoramic picture of the power of this material for drug delivery applications. 
Antitumoral drugs have been loaded within the pore matrix of PSiNP producing 
nanocarriers able to destroy tumoral cells. Xia et al. have reported the fabrication of 
PSiNP functionalized with styrene groups in order to retain high amounts of 
doxorubicin (660 µg·mg-1) by π-π stacking between the aromatic rings of styrene and 
doxorubicin (Dox), respectively. The same research group has employed bovine serum 
albumin grafted on the particle surface in order to increase the colloidal stability of the 
system and also for loading Dox by electrostatic interactions.[47] Both systems are able 
to release the retained Dox at mild-acidic pH. RNA interference encapsulated within 
small liposomes (30-40 nm) has been trapped within PSiNP in order to silence 
oncoproteins which play key role in tumoral progression.[48] The administration of one 
single injection of this system in a murine model of ovarian cancer was capable, not 
only to reduce the tumor burden, but also to hamper angiogenesis and tumoral cell 
proliferation without observing toxicity in the host. Voelker et al. have reported the use 
of PSi nanodiscs decorated with antibodies as targeted antitumoral nanocarriers.[49] In 
this work, MLR2 anti-p75 antibodies were grafted on the particle surface enhancing its 
selectivity for neuroblastoma cells (SH-SY5Y) which overexpress p75NTR 
neurotrophin receptors. These targeted nanodiscs were loaded with camptothecin 
showing high cytotoxicity and selectivity against the tumoral cells. Ferrari et al. has 
employed an engineered thioaptamer able to recognize E-selectin for achieving selective 
homing of PSi microparticles to bone marrow.[50] The employed thioaptamer 
specifically binds to E-selectin, which is usually expressed by the bone marrow 
endothelium, whereas it shows little affinity by other selectin family members. The 
surface of PSiNP can be decorated not only with targeting molecules but also with 
imaging agents giving place to theranostics devices, i.e. nanocarriers able to deliver 
therapeutic compounds and to provide information by imaging techniques about their 
biodistribution or therapeutic efficacy in real time. In a recent paper, a theranostics 
PSiNP has been synthesized placing iRGD as targeting agent and 111In-DOTA and 
Alexa-Fluor 488 as single photon emission computed tomography (SPEC) and 
fluorescent agent, respectively.[51] This device combines the enhanced selectivity 
against metastatic prostate cancer provided by iRGD, a dual-modality imaging capacity 
and a controlled antitumoral drug release. Polymeric coatings can be placed on the 
particle surface in order to control the release kinetic of the housed drugs. Chitosan 
coating has been employed with this purpose on the surface of oligonucleotide-loaded 
PSiNP.[52] The positive charge of this polymer promotes its adhesion by electrostatic 
interactions on the negatively charged particle surface. Additionally, the resulting 
particle presents a positive surface which facilitates the interaction with cell membranes 
and therefore, the particle uptake. In the case of naked particles, the retained 
oligonucleotides are rapidly released (80% of the cargo is released in the first 4 hours) 
whereas it requires more than 35 hours when the particles are coated.  
PSiNP can be loaded with two or more species, even with molecules which present very 
different nature, in order to combine several therapeutic effects, or to beat the acquired 
drug resistance of tumoral cells (Figure 3). 
Thus, indomethacin, a hydrophobic anti-inflammatory drug and hydrophilic peptides as 
PYY3-36, a 36 aminoacids peptide that inhibit the appetite, were effectively loaded 
within PSiNP showing acceleration in their release profile and higher drug permeation 
in tissue models as a consequence of their mutual influence.[53] In other recent work, 
methotrexate, a folic acid analog which is used as antitumoral drug was chemically 
grafted on amino-functionalized PSiNP walls and sorafenib, an anti-angiogenic 
hydrophobic drug, was loaded within the pore network.[54] This material shown fast 
release of the hydrophobic drug thanks to the highly porous nature of the carrier and 
prolonged release of methotrexate, as a consequence to the need to break the covalent 
bond which maintains this molecule attached to the surface. This particular release 
kinetic could be exploited for achieving a rapid angiogenesis inhibition followed by 
tumoral cell death.  Weitz et al. have reported an assembled nanocarrier composed by 
PSiNP embedded within giant liposomes. This device is able to deliver different species 
such as hydrophilic and hydrophobic drugs, DNA nanostructures, gold nanorods and 
iron oxide nanoparticles.[55] The presence of the metallic cores provides responsive 
capacities under photothermal and magnetic exposition because the heat generated by 
the application of these stimuli distorts the lipid bilayer. The combined release of 
different cytotoxic drugs in combination with the release of certain DNA nanostructures 
engineered to enhance the action of the antitumoral drugs have demonstrated the 
capacity to destroy multi-drug resistance breast cancer cells, which are resilient to the 
administration of these cytotoxic drugs alone.   
These types of particles are uptaked by tumoral cells through endocytosis in a similar 
way that MSNs and the vast majority of nanocarriers. Thus, endosomal escape is of 
paramount importance in order to reach the cytosol avoiding the aggressive 
environment usually present in late endosomes or lysosomes. This fact is even more 
dramatic in the case of the transportation of labile molecules as proteins, DNA, RNA, 
etc. Santos et al. have reported the use of a zwitterionic polymer coating composed by 
polyethylene imine (PEI) and poly(methyl vinyl ether-co-maleic acid) (PMVE-MA). 
This polymer shell provides several interesting advantages such as increased colloidal 
stability caused by electrostatic repulsion between the particles, endosomal escape as a 
consequence of proton sponge effect originated by the presence of tertiary amines in 
PEI and finally, a sustained drug release behavior due to the polymer coating.[56]  
Finally, similarly to the case of MSN although much less exploited, different stimuli-
responsive gatekeepers can be anchored on the pore outlets in order to control drug 
departure. Thus, cyclodextrins have been anchored on the pore entrances using 
supramolecular interactions which can be broken at mild acidic conditions.[57] pH-
sensitive polymers as poly(beta-amino esters) have also been employed as gate-keepers 
in this type of material. [58]  
4. METAL-ORGANIC FRAMEWORKS (MOFs) 
Coordination polymers (CPs) have emerged as a novel family of nanostructured 
materials for encapsulation and drug release applications over the last years.[59] 
Advantages, if properly addressed, are multifold:  (i) nanoscale CPs show intrinsic 
benefits associated with its hybrid nature, i.e. the combination of metal ions and organic 
ligands; (ii) they exhibit a high synthetic flexibility as long as metal-ligand bonds 
exhibit directional interactions that can be used to systematically control and tune their 
dimensionality; (iii) CPs have magnetic, electronic, optical, and catalytic properties 
associated with the limitless choice of metallic elements they can contain and (iv) 
different metal elements have ubiquitous functions in natural biological systems. 
Therefore, although CPs in crystalline forms date are known for many years, their 
miniaturization to the nanometer scale has represented a novel opportunity to develop a 
unique class of highly tailorable functional materials that combine the rich diversity of 
CPs with the advantages of nanomaterials. 
Two different approaches schematically represented in Figure 4 have already been 
followed for the encapsulation and controlled release of antitumoral drugs:[60] I) 
amorphous coordination polymer nanoparticles, refereed from now on as nanoscale 
coordination polymers (NCPs)[61] and II) nanoscale crystalline and porous 
coordination polymer structures, referred from now on as NMOFs 
Although nanoscale NCPs do not exhibit an open-framework structure, they have 
already shown great potential for encapsulation of different drugs with yields up to 20% 
[62] and improved IC50 values with respect to the corresponding free drug [63]. In 
these systems, encapsulation takes place through a physical entrapment of the drug 
within the amorphous polymeric internal structure of the nanoparticles. However, much 
better encapsulation yields and modified release profiles can be obtained by 
incorporating the drugs as constitutive units of the coordination network in the form of 
active ligands or with connecting metal ions such as Pt(IV) complexes.[64]  
On the contrary, NMOFs exhibit tunable pores with an exceptionally high surface area 
and high loading capacities. [65]  Their geometries, size, and functionalities can be 
systematically varied to yield architecturally robust porous structures with a typical 
porosity up to 50% of the crystal volume. These materials exhibit a wide range in pore 
diameter between 2-50 nm, similarly to the materials described above. Accordingly 
surface areas can range from 1000 to 10,000 m2/g, much higher than those of other 
traditional porous materials such as zeolites and carbons. Therefore, encapsulation 
usually takes place within the pores though some authors such as Monti et al. have 
demonstrated that drug encapsulation can also be mediated through the reactivity of the 
drug with the metal ions of the framework.[66]  For this, MIL-100(Fe) nanostructures of 
∼200 nm diameter were loaded with DOX and the binding constants determined via 
absorption and fluorescence titrations. Spectroscopic data indicated that DOX binding 
occurs via the formation of highly stable coordination bonds between one or both 
deprotonated hydroxyl groups of the aglycone moiety and coordinatively unsaturated 
Fe(III) centers. Alternatively, other area of interest within the field is the 
functionalization of the NMOFs to improve their colloidal stability and 
biocompatibility. In this direction, Bein et al. have demonstrated that MOF@lipid 
systems can effectively store dye molecules inside their porous scaffold while the 
addition of a protective lipid bilayer: I) prevents their premature release, II) increases 
the colloidal stability of the nanoparticles and III) favors a high uptake of lipid coated 
nanoparticles by cancer cells (Figure 5).[67] 
Finally, as far as the loading of active drugs within MOFs is concerned, the group of 
Ferey is considered one of the pioneering groups. Back in 2006, they already 
demonstrated that MIL-101 (Cr) can adsorb 138 wt % ibuprofen and MIL-53 can adsorb 
22 wt % ibuprofen. The release of ibuprofen from the MILs was evaluated using 
simulated body fluid at 37 °C. It was found that the MIL-101 (Cr) released ibuprofen 
slowly in several stages, reaching completion after 6 days.[68] The MIL-53 materials 
showed an even slower release, reaching completion after 21 days.[69] Lin et al. have 
also been pioneers to show the potential application of NMOFs in magnetic resonance 
imaging and anticancer drug delivery applications.[70]   
As previously described, NMOFs have already been demonstrated to be excellent 
carriers for drug delivery applications.  Among the different therapeutic areas of 
interest, recent advances in the development of NMOFs for drug delivery have been 
specifically focalized in antitumoral applications, which are summarized next.  
As far as the encapsulation of antitumoral drugs is concerned, Li et al. reported back in 
2009 the synthesis of the MIL-101 NMOF and its loading with an organic fluorophore 
and an anticancer drug via covalent modifications of the as-synthesized 
nanoparticles.[71] Afterwards, Horcajada, Greft et al.[72] encapsulated antitumoural 
and retroviral drugs such as busulfan, azidothymidine triphosphate, doxorubicin or 
cidofovir within non-toxic porous iron(III)-based metal–organic frameworks with high 
loadings. Beyond the encapsulation process, these authors also demonstrated the 
potential association of therapeutics and diagnostics. Since then, the number of 
examples describing the potential use of NMOFs with antitumoral applications has 
considerably increased, as summarized next. 
4.1. Single reports of small drugs 
Wong et al. have reported the loading of a dinuclear gold(I) pyrrolidinedithiocarbamato 
complex within a Zn2+-based metal–organic framework (Zn-MOF) with in vitro 
cytotoxic activities towards A2780cis cisplatin-resistant ovarian cancer cells. 
Interestingly, drug-release testing was done using a set of transwell assay-based 
experiments instead of the conventional dialysis approach.[73] Zr-based UiO-66 cubical 
nanostructures with average diameters of 70 nm were also reported by Shi et al. to 
load Alendronate (AL), a bisphosphate anticancer drug. Cytotoxicity assays in HepG2 
and MCF-7 cells showed that these nanostructures enhance cell killing by comparison 
with free AL.[74] Alternatively, Wang et al. developed Zn2+ or Cu2+ NMOFs, using the 
cytotoxic ligand, 3,5-bis(pyridine-3-ylmethylamino)benzoic acid, which exhibited 
cytotoxicity effects in three human cancer cells (NCI-H446, MCF-7 and HeLa).[75]  
An enjoyable example of the advantages of drug encapsulation was given by Gref at el. 
[76]  These authors encapsulated the highly hydrophilic prodrug phosphated gemcitabin 
(Gem-MP), known for its instability and inability to bypass cell membranes, within 
MIL-100 NMOFs. Interestingly, the storage stability of the loaded NMOFs was strongly 
dependent on the media; indeed, while the NMOF turns out to be stable in water at least 
for three days significant release was found in media containing phosphates since it 
induces its particle degradation. Moreover, the drug-loaded NMOFs were effective 
against pancreatic PANC-1 cells in contrast to free drug and empty NMOFs, which 
apparently did not show any cytotoxic effect.  
Finally, multifunctional systems combining anticancer activity and imaging capacities 
have also been a target of interest. With this aim Sahu et al. have incorporated Fe3O4 
nanoparticles, used as an MRI contrast agents, into nanostructures smaller than 100 nm 
of the porous isoreticular IRMOF-3.[77] Such nanostructures were subsequently 
conjugated with folic acid (to achieve targeted drug delivery towards cancer cells) and 
the fluorescent rhodamine B isothiocyanate (RITC) (for biological imaging), and loaded 
with the hydrophobic anticancer drug paclitaxel. In vitro biological toxicity studies 
revealed that the resulting nanoparticles targeted and killed the cancer cells in a highly 
effective manner. 
4.2. Encapsulation and controlled release of most common drugs 
4.2.1. Camptothecin and Doxorubicin 
In a recent work crystals of the well-known ZIF-8 were loaded with Doxorubicin 
(DOX) and used as efficient drug delivery carriers with efficacies on breast cancer cell 
lines remarkably higher than those found for free DOX.[78] Yamauchi et al. used the 
same family of ZIF-8 NMOFs to encapsulate 0.049 g DOX/g ZIF-8; in this case, 
cytotoxicity studies against three different human cancer cells (NCI-H292, HT29 and 
HL-60) resulted in a moderate activity by comparison with free DOX.[79] Moderate 
cytotoxicity versus leukemia cell line U937 was also found for Gd-based nanostructures 
of ∼140 nm obtained upon mechanical downsize from bulk MOFs via ball milling and 
encapsulating up to 12 wt % of DOX.[80] In a further work, NMOFs of the MIL-101 
loading doxo were developed by a one-pot synthesis and its premature drug release 
controlled upon surface modification with a pH responsive benzoic imine bond and a 
redox active disulfide system. Accordingly, in vitro and in vivo results demonstrated 
how this system exhibited effective cancer cell inhibition while having reduced side 
effects.[81] 
4.2.2. Methotrexate 
Gd-BDC nanorods coated with Methotrexate (MTX), PNIPAM-co-PNAOSco-PFMA-
MTX, and further linked with a targeting ligand GRGDS-NH2 were shown to exhibit 
enhanced cytotoxicity in sarcoma cells FITZ-HAS as compared to nontargeted NMOFs. 
Moreover, and thanks to the presence of the gadolinium ions, the nanoorods have 
simultaneous MRI activity.[82] MTX has also been used as a bridging ligand in 
NMOFs combined with Zn2+ or Gd3+ metal ions, resulting in astonishing high drug 
loadings (up to 79 wt %). The spherical nanostructures, with diameter ranging from 40 
to 100 nm, were stabilized with a lipid bilayer and targeted with anisamide. Efficient 
cellular uptake was confirmed by confocal microscopy studies though cytotoxicity 
studies revealed a behavior comparable to that of free drug.[83] Qian et al. also 
encapsulated MTX with high yields into inner pores and channels of the porphyrin-
based MOF PCN-221 by diffusion and controlled its posterior release under 
physiological environment without “burst effect”.[84] While the empty MOF 
framework exhibited low cytotoxic effects on the PC12 cells, the controlled pH release 
of the corresponding loaded nanoparticles revealed its activity in oral drug delivery. 
4.2.3. 5-Fluorouracil 
This is without any doubt one of the antitumoral drugs most widely loaded within 
NMOFs, as confirmed by the numerous examples so far reported. For instance, very 
recently Yang et al. have described microporous UiO-66-NH2 particles loading the drug 
and [2]pseudorotaxanes as gates of the nanocarriers linked via host–guest complexation 
to regulate the drug-controlled release.[85] 
More emphasis has been given to Zn-based NMOFs. Wang et al. used zinc and the 
hexadentate ligand 5,5′,5″-(1,3,5-triazine-2,4,6-triyl)tris(azanediyl)triisophthalate 
(TATAT) to prepare a chiral nanoporous MOF with high porosity. Afterwards, the 
antitumoral drug 5-Fu was loaded with high yield (about 50% of the transported drug 
versus the carrier material) and shown to be slowly released with a complete delivery 
time of about one week.[86] Other authors have reported a Zn3(L) MOF that can 
accommodate up to 0.36 mg of 5-Fu per mg MOF combined with lanthanide (III) 
cations for luminescence applications.[87] Loading of 5-Fu in into the well-known ZIF-
8 NMOFs have also been reported on different examples. For instance, Wang et al. 
reported control over the loading of 5-Fu into ZIF-8 NMOFs with a amount up to ∼40 
wt % and the posterior release under a pH sensitive environment.[88] Lan et al. also 
demonstrated that ZIF-8 MOFs could load 5-Fu with high loading amounts (31 wt %) 
and 5-Fu could diffuse out of the framework without burst.[89] Wang et al. showed that 
ZIF-8 NMOFs with a diameter of 100−200 nm by TEM could carry both 5-Fu and 
green fluorescent C-dots for pH-responsive drug release and fluorescence imaging.[90] 
Other authors developed three polyoxometalates (POMs) and loaded the POMs into 
ZIF-8 NMOFs with an average size of 50−200 nm.[91] The authors demonstrated that 
the incorporation of POMs into the frameworks led to more efficient loadings of 5-Fu 
and slow release of 5-Fu from the particles. Zhang et al. have very recently studied the 
biocompatibility and biodistribution of fluorouracil loaded ZIF-8 nanoparticles (ZIF-
NPs). A surprising high concentration was found in lung though the drug levels drop 
dramatically with time, revealing the fast degradation and elimination of these 
nanosystems. Accordingly, at the given doses, ZIF-NPs exhibit reasonably biosafety in 
animal tests as evidenced by their acceptable system and blood biocompatibilities, and 
minimal impacts on the liver and renal functions, immune cells, inflammatory factors, 
etc. However, ZIF-NPs with fluorouracil loading (5Fu@ZIF-NPs) significantly improve 
the therapeutic outcome of lung metastasis tumor in a nude mice model.[92] 
Finally some examples of copper-based MOFs have been reported. For example, Ng et 
al. reported MOFs with a formula of [Cu(L)(4,4′-bipy)(H2O)], where H2L stands for  
diphenylmethane-4,4′-dicarboxylic acid, loaded with amounts of 5-Fu up to 28 wt 
%.[93] Nascimento and co-workers reported the synthesis of a Cu-BTC MOF 
incorporating the 5-Fu drug with yields of ∼45 wt %.[94] The cytotoxicity of drug 
loaded MOFs was evaluated in different cell lines (NCI-H292, MCF-7, HT29 and 
HL60) showing enhanced cytotoxicity mainly in MCF-7 and HL60 cells. In a further 
example, Zhou et al. synthesized a Cu-based MOF with conjugated PEG5K on the 
surface via click chemistry resulting in PEGylated MOF nanoparticles of ∼50 nm that 
allow for the controlled loading and release of the drug.[95] 
4.2.4. Platinum and Ruthenium 
NMOFs based on the assembly of Zn2+ metal ions and a functionalized pyrazol-based 
organic spacer have been recently reported by Barea et al.[96] These system were 
shown to exhibit excellent colloidal stabilities under different relevant intravenous and 
oral-simulated physiological conditions, fact that the authors attributed to the formation 
of a protein corona on their surface. Furthermore, two antitumor drugs (mitroxantrone 
and [Ru(p-cymene)Cl2(pta)] (RAPTA-C) where pta =1,3,5-triaza-7-phospaadamantane) 
were encapsulated with a loading capacity that directly depends on the surface area of 
the solids and its functionalization. 
Multifunctionality has also been explored by Morris et al. upon combined loading of 
platinum and ruthenium drugs with NO. For instance, incorporation of cisplatin and a 
Pt(IV) cisplatin prodrug into two zirconium-based UiO66 and UiO66-NH2 MOFs 
following two different approaches has been reported.[97] In the first route, the Pt(IV) 
cisplatin prodrug was incorporated into UiO66-NH2 through an amide coupling reaction 
with the NH2 groups whereas in the second route, cisplatin was encapsulated into the 
large cavities of both MOFs. The cytotoxicity of the formulations was assessed on the 
A549 lung cancer cell line showing that the cisplatin loaded MOF turns out to be more 
efficient because its higher loading capacity. The same authors also investigated the 
multifunctionality of these systems by incorporation of the antithrombotic NO into the 
drug-loaded MOFs; surprisingly, the amount of NO released from these formulations is 
much greater than that from the pure MOFs. Morris and co-workers further loaded not 
only platinum but also the chemotherapeutic agent, [Ru(p-cymene)Cl2(pta)] (RAPTA-
C), along with NO into the same MOF by direct interaction with the Ni open metal sites 
and physically entrapment, respectively. The loading efficiency of NO and RAPTA-C 
was not affected by the presence of each other. However, the presence of RAPTA-C in 
the MOFs significantly retarded the desorption of NO under a humid flowing gas. MIL-
88(Fe) MOFs were also exploited as the delivery vehicle for NO by Morris and co-
workers. A significant amount of NO was adsorbed at room temperature by the 
nontoxic, biodegradable, and flexible MIL-88(Fe) MOFs at a high loading amount of 
1−2.5 mmol/g. NO was released from MOFs over a long period of time (>16 h), 
suggesting these MOFs can adsorb NO with high efficiency and release NO in a 
controlled manner.[98] 
Multifunctionality has also been reported with other systems beyond NO. For example, 
Lin and co-workers reported the first use of NMOFs for the combined delivery of 
cisplatin and pooled siRNA.[99] For this, cisplatin and a pool of siRNAs targeting 
multidrug resistant genes were loaded into UiO hexagonal plate like NMOFs with ∼100 
nm diameter and ∼30 nm thickness with high loading amounts. Interestingly, these 
systems efficiently delivered both siRNA and cisplatin to four cisplatin-resistant human 
ovarian cancer cells (ES-2, OVCAR-3, SKOV-3 and A2780/CDDP) decreasing the 
cisplatin IC50 values by an order of magnitude as compared to free cisplatin. This 
efficacy increase was attributed to the activation of the drug resistant gene from the 
ovarian cancer cells to cisplatin mediated by siRNA/UiO-Cis NMOFs. 
5. CONCLUSIONS 
Even though porous materials are still far from becoming a real and widely 
approved solution for drug delivery into the market, these materials have already 
shown their versatility and efficiency in many crucial areas of relevance, from 
high yield encapsulation to targeted cytotoxicity. Comparatively, most of the 
work has been done on mesoporous silica nanoparticles by comparison with the 
two other approximations having some prototypes in clinical trials. 
First reports on the use of PSiNP and NMOFs for antitumoral applications were 
described less than a decade ago but since then the number of citations and papers 
being reported in the area is increasing exponentially. Much of the work so far 
devoted is focussed on fundamental concepts of increasing loading encapsulation 
yields, surface functionalization and the interaction of drug with different 
carriers. Though, work in the near future should be concentrated more on their 
colloidal stability, permeability and drug release responses in real biological 
environments. 
 
6. EXPERT OPINION 
6.1 General Comments 
Porous nanoparticles constitute one of the most promising materials for clinical use in 
the treatment of cancer. Advantages are multifold: I) they exhibit a great loading 
capacity clearly higher than the capacity shown by other organic systems as 
polymersomes, micelles, liposomes, or definitely over non-porous inorganic materials, 
II) trapped drugs can be released in a controlled manner both placing stimuli-
responsive gatekeepers on their external surface as well as modifying the inner pore 
walls in order to release the cargo under certain conditions and III) the solid nature of 
the carrier provides high protection to the trapped species against the aggression of 
external agents. Most of the successful examples so far reported with hybrid porous 
materials for drug delivery in antitumoral applications are based on mesoporous silica 
nanoparticles and porous silicon to a lesser extent. On the contrary, though successful 
examples have already been reported, much work is needed for NMOFs. Efforts in this 
direction are already being undertaken through the introduction of a large number of 
different functional groups within the pores of MOFs. This yields multivariate 
frameworks in which the varying arrangement of functionalities gives rise to materials 
that offer a synergistic combination of properties. Another area to be studied with more 
detail in NMOFs is their biodistribution and accumulation, including cellular transit, 
degradation, excretion, physiological barrier penetration, and chronic toxicity. In vivo 
studies of the pharmacokinetics and efficiency of drug-containing NMOFs should be the 
next major steps to evaluate their real performance in medicine. Nevertheless, and albeit 
yet at relative early stages of development, we do believe that the precise chemical 
control that is possible to attain over the assembly of NMOFs will definitely propel this 
field further into new realms of synthetic chemistry in which far more sophisticated 
materials may be accessed. For example, materials can be envisaged as having (i) 
compartments linked together to operate separately, yet function synergistically; (ii) 
dexterity to carry out parallel operations; (iii) ability to count, sort, and code 
information; and (iv)capability of dynamics with high fidelity. 
6.2 Size and shape 
Another area of relevance is that of the final dimensions of the nanostructures. Indeed, 
the collapse of lymphatic vessels within a tumor facilitates the retention of extravasated 
nanoparticles in the tumoral area; nevertheless, this also causes the apparition of 
interstitial fluid pressure which strongly hampers their diffusion within the zone. 
Therefore, the action of these nanomedicines is restricted to the periphery of the tumors 
which drastically reduces their therapeutic efficacy. As a general rule to overcome this 
limitation, smaller sizes of nanocarrier achieve deeper penetrations. However, higher 
sizes yield better discrimination between healthy and tumoral tissues. Therefore, it is 
necessary to optimize the size carrier for each type of tumor. MSNs can be easily 
prepared with a wide range a shapes, sizes and external functionalization.[12] The 
influence of these parameters in cell uptake processes have been widely studied 
showing that the aspect ratio and surface charge play an important role in cell 
internalization and this process is highly cell dependent.[100] Additionally, in the case 
of intravenous administration (that is the usual case for antitumoral therapy) it is 
necessary to take into account the influence of these parameters in the interaction of the 
nanocarriers with the blood cells. However, in most cases these parameters have been 
evaluated using simplistic in vitro models and much work is required in order to know 
their significance in animal models. NMOFs with good dimensions between tens of 
nanometers and a few hundred nanometers have been reported though with some 
irregular shapes in some cases, plate-like structures or not perfectly round-shaped 
nanoparticles. Therefore detailed studies about the effect of the shape would be 
required. Another limitation of nanocarrier diffusion is caused by the high collagen 
density present in tumoral tissues. In order to improve the diffusion, proteolytic 
enzymes have been administered a few days before nanoparticle administration, or even 
these enzymes have been anchored on the particle surface.[36] In the case of porous 
nanoparticles, their lack of flexibility may difficult even more the penetration in living 
tissues and the barriers mentioned above play an even more important role. Thus, it is 
compulsory to take into account these barriers in order to design a suitable nanocarrier 
for future developments.  
6.3 Surface functionalization 
Another area of relevance lies at the surface functionalization of the nanoparticles and 
their effect on their improved stabilities and cell internalization. Indeed, one of the main 
advantages of nanoparticles as drug carriers for oncological applications is their passive 
accumulation within tumoral lesions by EPR effect. Once there, the presence of 
targeting agents attached on the particle surface enhances their uptake in these diseased 
cells, without affecting the healthy ones which are also present in the tissue. This fact 
allows the selective destruction of malignant cells. However, despite the good outcomes 
observed in in vitro experiments, only a few targeted nanodevices have demonstrated 
good performance in animal models. There are several reasons which contribute to this 
failure. One of them is that when a nanocarrier comes into contact with blood, it is 
immediately covered by a protein layer called protein corona. This corona masks the 
targeting agents which are the real readable part of the nanocarrier. Thus, the fate of the 
nanocarrier is not ruled by the presence of the targeting agents on the surface but it 
depends on the proteins bound to the particle surface. Additionally, the presence of the 
protein corona usually accelerates the particle clearance by the mononuclear phagocytic 
system (MPS). These limitations can be alleviated grafting the targeting agents 
employing hydrophilic or zwitterionic polymers as spacers. These polymers avoid 
protein adsorption enhancing the circulating time and they also present more effectively 
the targeting agents to tumoral cell receptors. Another issue which limits the in vivo 
nanocarrier performance is the high complexity and heterogeneity of the tumoral mass 
which not only present several types of tumoral cells but it also contains a huge number 
of non-tumoral cells as mesenchymal, immune, supportive cells, etc. which play an 
important role in tumor progression. In many cases, the efficacy of targeted nanodevices 
is tested employing simplified in vitro models which contain only the tumoral cell. It is 
true that in vitro models provides valuable information about the recognition process 
between the targeting agent and the specific tumoral cell receptor but, before reaching in 
vivo evaluation, it should be necessary to evaluate this capacity employing more 
realistic models such as 3D tissue models or tumor spheroids which contains a 
representative mixture of tumoral and non-tumoral cells, as well as cells from the 
immune systems. Finally, another drawback associated with the use of targeted 
nanomedicines is the binding site barrier, which is caused by the strong affinity 
between the targeting moiety and its receptor. This fact provokes that nanomedicines 
are firmly bound to the first cell line near tumoral blood vessels exacerbating even more 
the poor penetration problem mentioned above. One way to reduce this effect is to 
employ stimuli-responsive targeting agents which travel through the body in a hidden 
conformation, whereas they can be activated by certain stimulus present in the tumoral 
area or externally applied.[101] Great success has been achieved on the surface 
functionalization of silica nanoparticles. A high number of synthetic strategies for the 
decoration of the external surface of MSN and PSiNP have been described. It is even 
possible to functionalize differently the external surface and inner pore walls. However, 
in many cases it is necessary to achieve a precise control of the orientation of the grafted 
biomolecule, as in the case of antibodies or other recognition moieties.  In this sense, it 
would be very useful to employ the wide arsenal of synthetic alternatives which 
provides the bioorthogonal chemistry.[102] Once more, surface functionalization is less 
common for NMOFs most of the times limited to the reactivity of some metal ions lying 
at the surface of the nanostructures or mainly to some polymeric or lipidic coatings.  
Another limitation, not only for porous nanoparticles but common to several 
nanocarriers, lies in the fact that passive accumulation by EPR effect is not always 
guaranteed because this phenomenon is not universal. It not only depends on the tumor 
type but it also exhibits great heterogeneity within one tumoral lesion. Additionally, 
EPR undergoes variations during the treatment. Thus, tumors which exhibit a significant 
EPR effect at the beginning of the treatment could show scarce passive accumulation 
after some cycles of treatment. Therefore, it is necessary to monitor the vascular 
architecture of the tumoral lesion before recommending a treatment based on 
nanomedicines. It is possible to enhance the EPR effect through the previous 
administration of drugs as angiotensin I-converting enzyme (ACE) inhibitors or NO 
releasing agents.[4]  
It is important to keep in mind that the design of a nanocarrier able to overcome all of 
these barriers would be pointless, because it would require to build really complex 
systems, difficult to approve by regulatory agencies.[103] The administration of diverse 
types of nanocarriers, each of them responsible for different tasks, could be simpler and 
more efficient than the design of one single carrier able to perform all of them. There 
are a few examples of cooperative work between nanoparticles in which, for example 
one of them facilitates the extravasation of the second one in the tumoral area,[104] but 
more efforts are needed in this point. As was pointed out above, there are many 
parameters which affect the efficacy of these types of nanocarriers and more knowledge 
is needed in order to find solutions for them. For the design of the next generation of 
novel porous inorganic nanocarriers we have to bear in mind the well-known quote in 
the engineering world “embrace complexity, design versatility and deliver simplicity”. 
  
Funding 
The authors acknowledge financial support from Spanish Government through the 
project MAT2015-64831-R and MAT2015-70615-R and by FEDER funds. D Ruiz-
Molina thanks ICN2-CSIC, Spain for infrastructural and financial support and specially 
the students and collaborators for their contribution. ICN2 acknowledges support from 
the Severo Ochoa Program (MINECO, Grant SEV-2013-0295). M Vallet-Regíis grateful 
thanks the financial support through ERC-2015-AdG VERDI. 
 
Declaration of interest 
The authors have no relevant affiliations or financial involvement with any organization 
or entity with a financial interest in or financial conflict with the subject matter or 
materials discussed in the manuscript. This includes employment, consultancies, 
honoraria, stock ownership or options, expert testimony, grants or patents received or 
pending, or royalties. 
 
 
  
References 
Papers of special note have been highlighted as either of interest (•) or of 
considerable interest (••) to readers 
1.  Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem 
Soc 2016;138:704-17. 
2. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv 
Drug Deliv Rev 2012;64:24–36. 
3. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-
chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent 
smancs. Cancer Res 1986;46:6387–92. 
4. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to 
solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor 
imaging in vivo. Adv Drug Deliv Rev 2013;65:71–79. 
5. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin 
Oncol 2010;7:653–64. 
●Review of the principal mechanisms of EPR effect and the main limitations of the use of 
nanocarrier as antitumoral agents. 
6. [10]  Steichen SD, Caldorera-Moore M, Peppas N. A review of current nanoparticle and 
targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013;48:416–27. 
7.  Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer 
therapy. Nat Nanotechnol 2007;2:751-760. 
8. Nguyen KT, Zhao Y. Engineered hybrid nanoparticles for on-demand diagnostics and 
therapeutics. Acc Chem Res 2015;48:3016-25. 
9. Hoffmann F, Cornelius M, Morell J, et al. Silica-based mesoporous organic-inorganic 
hybrid materials. Angew Chem Int Ed 2006;45:3216–51. 
●●Review of the synthetic proccedures for the synthesis of MSNs and their mechanism.  
10. Chudley R, Greeno R. Fundamentals of Porous Silicon Preparation. Porous Silicon 
Pract. Prep. Charact. Appl. 2012, Chapter 1:1-42. 
11. Sapsford KE, Algar WR, Berti L, et al. Functionalizing nanoparticles with biological 
molecules: Developing chemistries that facilitate nanotechnology. Chem Rev 2013;113:1904–
2074. 
12. Trewyn BG, Slowing II, Giri S, et al. Synthesis and functionalization of a mesoporous 
silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem 
Res 2007;40:846–53. 
13. Yang P, Gaib S, Lin J. Functionalized mesoporous silica materials for controlled drug 
delivery. Chem Soc Rev 2012;41:3679-3698.  
14. Argyo C, Weiss V, Bräuchle C,et al. Multifunctional mesoporous silica nanoparticles as 
a universal platform for drug delivery. Chem Mater 2014;26:435-51 
15. Baeza A, Colilla M, Vallet-Regí M. Advances in mesoporous silica nanoparticles for 
targeted stimuli-responsive drug delivery. Expert Opin Drug Deliv 2015;12:319-37. 
16. Mal NK, Fujiwara M, Tanaka Y. Photocontrolled reversible release of guest molecules 
from coumarin-modified mesoporous silica. Nature 2003;421:350-53. 
17. Martínez-Carmona M, Baeza A, Rodriguez-Milla M, etal. Mesoporous silica 
nanoparticles grafted with a light-responsive protein shell for highly cytotoxic antitumoral 
therapy. J Mater Chem B 2015;3:5746–52. 
18. Yang S, Li N, Chen D, et al. Visible-light degradable polymer coated hollow 
mesoporous silica nanoparticles for controlled drug release and cell imaging. J Mater Chem B 
2013;1:4628–36. 
19. Wang D, Wu S. Red-light-responsive supramolecular valves for photocontrolled drug 
release from mesoporous nanoparticles. Langmuir 2016;32:632–6 
20. Dobay MP, Schmidt A, Mendoza E, et al. Cell type determines the light-induced 
endosomal escape kinetics of multifunctional mesoporous silica nanoparticles. Nano Lett 
2013;13:1047-52. 
21. Li H, Tan L-L, Jia P, et al. Near-infrared light-responsive supramolecular nanovalve 
based on mesoporous silica-coated gold nanorods. Chem Sci 2014;5:2804-8. 
22. Liu J, Wang C, Wang X, et al. Mesoporous silica coated single-walled carbon 
nanotubes as a multifunctional light-responsive platform for cancer combination therapy. Adv 
Funct Mater 2015;25:384-92. 
23. Xu F, Ding L, Tao W, et al. Mesoporous-silica-coated upconversion nanoparticles 
loaded with vitamin B12 for near-infrared-light mediated photodynamic therapy. Mater Lett 
2016;167:205–8. 
24. Chen H, Wang GD, Chuang Y-J, et al. Nanoscintillator-mediated x-ray inducible 
photodynamic therapy for in vivo cancer treatment. Nano Lett 2015;15:2249-56. 
25. Dong J, Zink JI. Taking the temperature of the interiors of magnetically heated 
nanoparticles. ACS Nano 2014;8:5199–207. 
26. Guisasola E, Baeza A, Talelli M, et al. Magnetic-responsive release controlled by hot 
spot effect. Langmuir 2015;31:12777–82. 
27. Baeza A, Guisasola E, Ruiz-Hernandez E, et al. Magnetically triggered multidrug 
release by hybrid mesoporous silica nanoparticles. Chem Mater 2012;24:517–24. 
28. Bringas E, Koysuren O, Quach D V, et al. Triggered release in lipid bilayer-capped 
mesoporous silica nanoparticles containing SPION using an alternating magnetic field. Chem 
Commun 2012;48:5647–49. 
29. Ruiz-Hernandez E, Baeza A, Vallet-Regi M. Smart drug delivery through dna/magnetic 
nanoparticle gates. ACS Nano 2011;5:1259–66. 
30.  Paris JL, Cabanas MV, Manzano M, et al. Polymer-grafted mesoporous silica 
nanoparticles as ultrasound-responsive drug carriers. ACS Nano 2015;9:11023–33. 
31.  Niedermayer S, Weiss V, Herrmann A, et al. Multifunctional polymer-capped 
mesoporous silica nanoparticles for pH-responsive targeted drug delivery. Nanoscale 
2015;7:7953-64. 
32.  Liu J, Luo Z, Zhang J, et al. Hollow mesoporous silica nanoparticles facilitated drug 
delivery via cascade pH stimuli in tumor microenvironment for tumor therapy. Biomaterials 
2016;83:51–65. 
33.  Qiu X-L, Li Q-L, Zhou Y, et al. Sugar and pH dual-responsive snap-top nanocarriers 
based on mesoporous silica-coated Fe3O4 magnetic nanoparticles for cargo delivery. Chem 
Commun 2015;51:4237-40. 
34.  Chen Y, Ai K, Liu J, et al. Multifunctional envelope-type mesoporous silica 
nanoparticles for pH-responsive drug delivery and magnetic resonance imaging. Biomaterials 
2015;60:111-20. 
35.  Li Z, Clemens DL, Lee BY, et al. Mesoporous silica nanoparticles with pH-sensitive 
nanovalves for delivery of moxifloxacin provide improved treatment of lethal pneumonic 
tularemia. ACS Nano 2015;9:10778-89. 
36.  Villegas MR, Baeza A, Vallet Regí M. Hybrid collagenase nanocapsules for enhanced 
nanocarrier penetration in tumoral tissues. ACS Appl Mater Interfaces 2015;7:24075-81. 
37.  Prasad R, Aiyer S, Chauhan DS, et al. Bioresponsive carbon nano-gated multifunctional 
mesoporous silica for cancer theranostics. Nanoscale 2016;8:4537-46. 
38.  Palanikumar L, Choi ES, Cheon JY, et al. Noncovalent polymer-gatekeeper in 
mesoporous silica nanoparticles as a targeted drug delivery platform. Adv Funct Mater 
2015;25:957–965. 
39.  Wu M, Meng Q, Chen Y, et al. Large pore-sized hollow mesoporous organosilica for 
redox-responsive gene delivery and synergistic cancer chemotherapy. Adv Mater 2016;28:1963-
9. 
40.  Lee J, Kim H, Han S, et al. Stimuli-responsive conformational conversion of peptide 
gatekeepers for controlled release of guests from mesoporous silica nanocontainers. J Am Chem 
Soc 2014;136:12880-3. 
41.  Maggini L, Cabrera I, Ruiz-Carretero A, et al. Breakable mesoporous silica 
nanoparticles for targeted drug delivery. Nanoscale 2016;8:7240-7. 
42. Tumors ML, Rijt SH Van, Bo Da, et al. Protease-mediated release of chemotherapeutics 
from mesoporous silica nanoparticles to ex vivo human. ACS Nano, 2015;9: 2377-89 
43.  Zhang P, Cheng F, Zhou R, et al. DNA-hybrid-gated multifunctional mesoporous silica 
nanocarriers for dual-targeted and microRNA-responsive controlled drug delivery. Angew 
Chem Int Ed 2014;53:2371-5. 
44.  Chen X, Cheng X, Soeriyadi AH, et al. Stimuli-responsive functionalized mesoporous 
silica nanoparticles for drug release in response to various biological stimuli. Biomater Sci 
2014;2:121. 
45.  Santos HA, Mäkilä E, Airaksinen AJ, et al. Porous silicon nanoparticles for 
nanomedicine: preparation and biomedical applications. Nanomedicine 2014;9:535-54. 
46.  Anglin EJ, Cheng L, Freeman WR, et al. Porous silicon in drug delivery devices and 
materials. Adv Drug Deliv Rev 2008;60:1266-77. 
●Review of the synthetic procedures and applications of porous silicon in medicine. 
47.  Xia B, Zhang W, Shi J, et al. A novel strategy to fabricate doxorubicin/bovine serum 
albumin/porous silicon nanocomposites with pH-triggered drug delivery for cancer therapy in 
vitro. J Mater Chem B 2014;2:5280. 
48.  Tanaka T, Mangala LS, Vivas-Mejia PE, et al. Sustained small interfering RNA 
delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96. 
49. Alhmoud H, Delalat B, Elnathan R, et al. Porous silicon nanodiscs for targeted drug 
delivery. Adv Funct Mater 2015;25:1137-45. 
50.  Mann AP, Tanaka T, Somasunderam A, et al. E-selectin-targeted porous silicon particle 
for nanoparticle delivery to the bone marrow. Adv Mater 2011;23:278-82. 
51.  Wang C-FC-F, Sarparanta MP, Mäkilä EM, et al. Multifunctional porous silicon 
nanoparticles for cancer theranostics. Biomaterials 2015;48:108-18. 
52.  Kafshgari MH, Delalat B, Tong WY, et al. Oligonucleotide delivery by chitosan-
functionalized porous silicon nanoparticles. Nano Res 2015;8:2033-46. 
53.  Liu D, Bimbo LM, Mäkilä E, et al. Co-delivery of a hydrophobic small molecule and a 
hydrophilic peptide by porous silicon nanoparticles. J Control Release 2013;170:268-78. 
54. Wang CF, Mäkilä EM, Kaasalainen MH, et al. Dual-drug delivery by porous silicon 
nanoparticles for improved cellular uptake, sustained release, and combination therapy. Acta 
Biomater 2015;16:206-14. 
55.  Kong F, Zhang X, Zhang H, et al. Inhibition of multidrug resistance of cancer cells by 
co-delivery of dna nanostructures and drugs using porous silicon nanoparticles@giant 
liposomes. Adv Funct Mater 2015;25:3330-40. 
56.  Shahbazi MA, Almeida P V., Mäkilä EM, et al. Augmented cellular trafficking and 
endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface 
engineering. Biomaterials 2014;35:7488–7500. 
57.  Xue M, Zhong X, Shaposhnik Z, et al. PH-operated mechanized porous silicon 
nanoparticles. J Am Chem Soc 2011;133:8798–801. 
58. Xu W, Thapa R, Liu D, et al. Smart porous silicon nanoparticles with polymeric coatings for 
sequential combination therapy. Mol. Pharmaceutics 2015;12:4038-47. 
59. Novio F, Simmchen J, Vázquez-Mera N, et al. Coordination polymer nanoparticles in 
medicine. Coord Chem Rev 2013;257:2839–47. 
60. He Ch, Liu D, Lin W. Nanomedicine applications of hybrid nanomaterials built from 
metal–ligand coordination bonds: nanoscale metal–organic frameworks and nanoscale 
coordination polymers. Chem Rev 2015;115:11079−108. 
61.  Della Rocca J, Liu D, Lin W. Nanoscale metal–organic frameworks for biomedical 
imaging and drug delivery. Acc Chem Res 2011;44:957-68. 
62. Imaz I, Rubio-Martínez M, García-Fernández L, et al. Coordination polymer particles as 
potential drug delivery systems. Chem Comm 2010;46:4737-9. 
63. Novio F, Lorenzo J, Nador F, et al. Carboxyl group ([bond]co2h) functionalized 
coordination polymer nanoparticles as efficient platforms for drug delivery. Chem Eur J 
2014;20:15443-50. 
64.   Rieter WJ, Pott KM, Taylor KML, et al. Nanoscale coordination polymers for platinum-
based anticancer drug delivery. J Am Chem Soc 2008;130:11584-5. 
65. Horcajada P, Serre C, Vallet-Regí M, et al. Metal–organic frameworks as efficient 
materials for drug delivery. Angew. Chem. 2006;118:6120-4.  
66. Anand R, Borghi F, Manoli F, et al.  Host-guest interactions in Fe(III)-trimesate MOF 
nanoparticles loaded with doxorubicin. J Phys Chem B 2014;118:8532−9. 
67. Wuttke S, Braig S, Preiß TS, et al. MOF nanoparticles coated by lipid bilayers and their 
uptake by cancer cells. Chem Commun 2015;51:15752-5. 
68. Horcajada P,  Serre C, Vallet-Regí M, et al. Metal-organic frameworks as efficient 
materials for drug delivery. Angew Chem Int Ed 2006;45:5974-8. 
69. Horcajada P, Serre C, Maurin G, et al. Flexible porous metal-organic frameworks for a 
controlled drug delivery. J Am Chem Soc 2008;130:6774-80. 
70.  Taylor KML, Rieter WJ, Lin W. Manganese-based nanoscale metal−organic 
frameworks for magnetic resonance imaging.  J Am Chem Soc 2008;130:14358-9. 
71. Taylor-Pashow KML,  Della Rocca J, Xie Z, et al. Postsynthetic modifications of iron-
carboxylate nanoscale metal−organic frameworks for imaging and drug delivery. J Am Chem 
Soc 2009;131:14261-3. 
72. Horcajada P, Chalati T, Serre C, et al. Porous metal–organic-framework nanoscale 
carriers as a potential platform for drug delivery and imaging. Nat Mat 2010;9:172-8. 
73. Sun RWY, Zhang M, Li D, et al. Dinuclear gold(I) pyrrolidinedithiocarbamato 
complex: cytotoxic and antimigratory activities on cancer cells and the use of metal–organic 
framework. Chem Eur J 2015;21:18534-8. 
74. Zhu XY, Gu JL, Wang Y, et al. Inherent anchorages in UiO-66 nanoparticles for 
efficient capture of alendronate and its mediated release. Chem Commun 2014;50:8779-82. 
75. Wang KB, Ma XY, Shao DL, et al. Coordination-induced assembly of coordination 
polymer submicrospheres: promising antibacterial and in vitro anticancer activities. Cryst 
Growth Des 2012;12:3786-91. 
76. Rodriguez-Ruiz V, Maksimenko A, Anand R, et al. Efficient “green” encapsulation of a 
highly hydrophilic anticancer drug in metal–organic framework nanoparticles.  J Drug Target 
2015;23:759-67. 
77. Chowdhuri AR, Bhattacharyab D, Sahu SK. Magnetic nanoscale metal organic 
frameworks for potential targeted anticancer drug delivery, imaging and as an MRI contrast 
agent.  Dalton Trans 2016;45:2963-73. 
78. Zheng H, Zhang Y, Liu L, et al. One-pot synthesis of metal–organic frameworks with 
encapsulated target molecules and their applications for controlled drug delivery.  J Am Chem 
Soc 2016;138:962-8. 
79. Torad NL, Li YQ, Ishihara S, et al. MOF-derived nanoporous carbon as intracellular 
drug delivery carriers.  Chem Lett 2014;43:717-9. 
80. Kundu T, Mitra S, Patra P, et al. Mechanical downsizing of a gadolinium(iii)-based 
metal–organic framework for anticancer drug delivery. Chem Eur J 2014;20:10514−8. 
81. Wang XG, Dong ZY, Cheng H, et al. A multifunctional metal–organic framework based 
tumor targeting drug delivery system for cancer therapy. Nanoscale 2015;7:16061-70. 
82. Rowe MD, Thamm DH, Kraft SL, et al. Polymer-modified gadolinium metal-organic 
framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and 
treatment of cancer. Biomacromolecules 2009;10:983-93. 
83. Huxford RC, Dekrafft KE, Boyle WS, et al. Lipid-coated nanoscale coordination 
polymers for targeted delivery of antifolates to cancer cells. Chem Sci 2012;3:198−204. 
84. Lin W, Hu Q, Jiang K, et al. J Sol State Chem 2016;237:307-12. 
85. Tan LL, Li H, Zhou Y, et al. Zn2+-Triggered drug release from biocompatible zirconium 
mofs equipped with supramolecular gates. Small 2015;11:3807-13. 
86. Sun CY, Qin C, Wang C, et al. Chiral nanoporous metal-organic frameworks with high 
porosity as materials for drug delivery. Adv Mater 2011;23:5629-32. 
87. Wang Y, Yang J, Liu YY, et al. Controllable syntheses of porous metal–organic 
frameworks: encapsulation of LnIII cations for tunable luminescence and small drug molecules 
for efficient delivery. Chem - Eur J 2013;19:14591-9. 
88. Sun CY, Qin C, Wang XL, et al. Zeolitic imidazolate framework-8 as efficient pH-
sensitive drug delivery vehicle. Dalton Trans 2012;41:6906-9. 
89. Qin JS, Du DY, Li WL, et al. N-rich zeolite-like metal–organic framework with sodalite 
topology: high CO2 uptake, selective gas adsorption and efficient drug delivery. Chem Sci 
2012;3:2114-8. 
90. He L, Wang TT, An JP, et al. Carbon nanodots@zeolitic imidazolate framework-8 
nanoparticles for simultaneous pH-responsive drug delivery and fluorescence imaging.  Cryst 
Eng Comm 2014;16:3259-63. 
91.  Li R, Ren X, Zhao J, et al. Polyoxometallates trapped in a zeolitic imidazolate 
framework leading to high uptake and selectivity of bioactive molecules. J Mater Chem A 
2014;2:2168-73. 
92. Li S, Wang K, Shi Y, et al. Novel biological functions of ZIF-NP as a delivery vehicle: 
high pulmonary accumulation, favorable biocompatibility, and improved therapeutic outcome.  
Adv Funct Mater 2016;26:2715-27. 
93. Liu JQ, Wu J, Jia ZB, et al. Two isoreticular metal–organic frameworks with CdSO4-
like topology: selective gas sorption and drug delivery. Dalton Trans 2014;43:17265-73. 
94. Lucena FR, de Araujo LC, Rodrigues Mdo D, et al. Induction of cancer cell death by 
apoptosis and slow release of 5-fluoracil from metal-organic frameworks Cu-BTC. Biomed 
Pharmacother 2013;67:707−13. 
95. Zhao D, Tan SW, Yuan DQ, et al. Surface functionalization of porous coordination 
nanocages via click chemistry and their application in drug delivery.  Adv Mater 
2011;23:90−93. 
96. Rojas S, Carmona FJ, Maldonado CR, et al. Nanoscaled zinc pyrazolate metal–organic 
frameworks as drug-delivery systems.  Inorg Chem 2016;55:2650-63. 
97. Mocniak KA, Kubajewska I, Spillane DEM, et al. Incorporation of cisplatin into the 
metal–organic frameworks UiO66-NH2 and UiO66-encapsulation vs. conjugation. RSC Adv 
2015;5:83648-56. 
98. McKinlay AC, Eubank JF, Wuttke S, et al. Nitric oxide adsorption and delivery in 
flexible mil-88(fe) metal–organic frameworks. Chem Mater 2013;25:1592-9. 
99.  He C, Lu K, Liu D, et al. Nanoscale metal–organic frameworks for the co-delivery of 
cisplatin and pooled sirnas to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. 
J Am Chem Soc 2014;136:5181-4. 
100.  Huang X, Teng X, Chen D, et al. The effect of the shape of mesoporous silica 
nanoparticles on cellular uptake and cell function. Biomaterials 2010;31:438-48. 
101.  Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor 
microenvironment. J Control Release 2015;219:205-14. 
102.  Algar WR, Prasuhn DE, Stewart MH, et al. The controlled display of biomolecules on 
nanoparticles: A challenge suited to bioorthogonal chemistry. Bioconjug Chem 2011;22:825-58. 
●●Review of the orthogonal chemical strategies for anchoring biomolecules on 
nanoparticles.   
103.  Venditto VJ, Szoka  Jr. FC. Cancer nanomedicines: So many papers and so few drugs! 
Adv Drug Deliv Rev 2013;65:80-8. 
104.  Park J-H, von Maltzahn G, Xu MJ, et al. Cooperative nanomaterial system to sensitize, 
target, and treat tumors. Proc Natl Acad Sci USA 2010;107:981–6. 
 
FIGURES 
 
 
 
Figure 1. Strategies for controlled release in MSNs 
  
 Figure 2. pH-sensitive collagenase nanocapsules grafted on MSNs for improved 
penetration in tumoral tissues 
  
 Figure 3. Multidrug delivery capacity in PSiNP 
 
 
  
 Figure 4. Schematic representation of the two different approaches followed with 
coordination polymers for their use as drug carriers.  
Reprinted with permission from He Ch, Liu D, Lin W. Nanomedicine applications of 
hybrid nanomaterials built from metal–ligand coordination bonds: nanoscale metal–
organic frameworks and nanoscale coordination polymers. Chem Rev 
2015;115:11079−108. Copyright 2016 American Chemical Society. 
  
 Figure 5. Schematic description of the synthesis of lipid bilayer-coated MOF 
nanoparticles loaded with dye molecules and their uptake in cancer cells.  
Reproduced with permission from S. Wuttke, S. Braig, T. Preiß, A. Zimpel, J. 
Sicklinger, C. Bellomo, J. O. Rädler, A. M. Vollmar and T. Bein, Chem. Commun., 
2015, 51, 15752 - Published by The Royal Society of Chemistry. 
 
